60 Degrees Pharmaceuticals shares are trading higher after the company announced ethics approval of an open label, expanded access study of the ARAKODA regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis.
$SXTP
Biotechnology: Pharmaceutical Preparations
Health Care
60 Degrees Pharmaceuticals shares are trading higher after the company announced ethics approval of an open label, expanded access study of the ARAKODA regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis.